Track the 한올바이오파마 stock price and the full directors' dealings record of the company, a listed issuer based in South Korea. Shares trade on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 한올바이오파마 has recorded 37 reports. The latest transaction was filed on 1 July 2026 (Purchase). Among the most active insiders: 국민연금공단. Every trade is free.
37
Insider Decl.
n/a
Thresholds
n/a
13 ops.
Buy Volume
n/a
13 ops.
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Hanall Biopharma is a company specializing in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative treatments for various diseases.